Dilutional Hyponatremia in Hospitalized Patients
This study will determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction. The objective of this study is to:
- Demonstrate that tolvaptan is superior to fluid restriction in safely reducing overall medically-necessary length of hospital stay in patients with dilutional hyponatremia, in part through improvement in hyponatremia symptoms
Approximately 400 subjects will participate in the study from about 90 sites in the United States. The Reading Hospital is currently enrolling patients in the study, which is expected to remain open until September 2013.
For more information, please call the Clinical Trials Office at 484-628-4308 or visit clinicaltrials.gov.